Patent SG-11201809253R-A (SG)
Title: Methods of treatment of diseases in which il-13 activity is detrimental using anti-il-13 antibodies
Inventor: TIMONY GREGG
IPC: C07K16/28
Filed: 2017-04-27
Abstract: WO 17 / 189805 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 02 November 2017 (02.11.2017) WIP0 I PCT omit VIII Hot 0 HE mollmomovoimIE (10) International Publication Number WO 2017/189805 Al (51) International Patent Classification: A61K 31/56 (2006.01) A61K 45/06 (2006.01) A61K 39/395 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2017/029768 (22) International Filing Date: 27 April 2017 (27.04.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/328,539 27 April 2016 (27.04.2016) US (71) Applicant: ABBVIE INC. [US/US]; 1 North Waukegan Road, North Chicago, IL 60064 (US). (72) Inventors: TIMONY, Gregg; 7333 Calle Pera, Carlsbad, CA 92009 (US). GUJRATHI, Sheila; P.o. Box 1395, Ran- cho Santa Fe, CA 92067 (US). PEACH, Robert; 3415 6th Avenue, San Diego, CA 92103 (US). OLSON, Allan; 3033 Science Park Rd., Ste. 300, San Diego, CA 92121 (US). (74) Agent: ZACHARAKIS, Maria, Laccotripe et al.; Mc- Carter & English, LLP, 265 Franklin Street, Boston, MA 02110 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, (54) Title: METHODS OF TREATMENT OF DISEASES IN WHICH IL-13 ACTIVITY IS DETRIMENTAL USING ANTI-IL-13 ANTIBODIES Baseline Week 16 Placebo (N=34) ®RPC4046 180 mg (N=31) El RPC4046 360 mg (N=34) FIG. 1 (57) : The present invention is directed to methods for treating diseases in which IL-13 activity is detrimental, including eosinophilic esophagitis (EoE) and asthma, by administering to a subject in need of such treatment, a composition containing an inter leukin- 13 (IL-13) antibody, or an antigen binding fragment, thereof. [Continued on next page] WO 2017/189805 Al MIDEDIMOMOIDEIROIDEMOMMEIHMOIREOMEMOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(H)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))